NRX Pharmaceuticals, Inc. Accounts Receivable, Allowance for Credit Loss
NRX Pharmaceuticals, Inc. (NRXP) had Accounts Receivable, Allowance for Credit Loss of $206.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-08-14
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss $206.00K.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss $181.00K.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $153.00K.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss $110.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $206.00K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $181.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $153.00K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $110.00K 10-Q · filed 2025-11-14 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-23 |
| 2021-06-30 | $5.47M 10-Q/A · filed 2022-08-12 |
| 2020-12-31 | $257.46K 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |